Bioaffinity technologies reports fourth quarter and full year 2022 financial results

San antonio--(business wire)--bioaffinity technologies, inc. (nasdaq: biaf; biafw), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and 12 months ended december 31, 2022.
BIAF Ratings Summary
BIAF Quant Ranking